<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01756547</url>
  </required_header>
  <id_info>
    <org_study_id>PRENECAL</org_study_id>
    <nct_id>NCT01756547</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature</brief_title>
  <acronym>PRENECAL</acronym>
  <official_title>Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan A. Arnaiz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess the efficacy and safety of oral potassium citrate on the Prevention of
      nephrocalcinosis in extreme premature: a clinical trial, randomized, double-blind placebo
      controlled trial.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of nephrocalcinosis in extremely preterm infants</measure>
    <time_frame>38-40 weeks of corrected gestational age</time_frame>
    <description>incidence of nephrocalcinosis in extremely preterm infants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine whether the administration of potassium citrate in extreme premature decreases neonates the levels of calcium and calcium / creatinine ratio in urine in each of the branches of treatment at 38-40 weeks</measure>
    <time_frame>38-40 weeks of corrected gestational age</time_frame>
    <description>Determine whether the administration of potassium citrate in extreme premature decreases neonates the levels of calcium and calcium / creatinine ratio in urine in each of the branches of treatment at 38-40 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine whether administration of potassium citrate improves the levels of urinary phosphorus, potassium, sodium, citrate, creatinine, oxalate, ratio citrate / calcium , and ph value</measure>
    <time_frame>38-40 weeks of corrected gestational age</time_frame>
    <description>To determine whether administration of potassium citrate in extreme premature infants improves the levels of phosphorus, potassium, sodium, citrate, creatinine, oxalate, and ratio citrate / calcium and ph in urine in each treatment arm at the 38-40 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine whether the administration of potassium citrate improves the plasma levels of sodium, potassium, creatinine, calcium, and ph value.</measure>
    <time_frame>38-40 weeks of corrected gestational age</time_frame>
    <description>Determine whether the administration of potassium citrate in extreme premature neonates improves the plasma levels of sodium, potassium, creatinine, calcium, and blood ph value in each of the branches of treatment at 38-40 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the incidence of adverse events and serious adverse events related to study treatment.</measure>
    <time_frame>38-40 weeks of corrected gestational age</time_frame>
    <description>To determine the incidence of adverse events and serious adverse events related to study treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Nephrocalcinosis</condition>
  <arm_group>
    <arm_group_label>Potassium citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral solution 30ml, that contains distilled water and simple syrup, in the same dose like the active treatment 0,3ml/kg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium Citrate</intervention_name>
    <description>Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age or unacceptable toxicity develops.</description>
    <arm_group_label>Potassium citrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Premature infants of both sexes born at the Hospital Clinic of Barcelona.

          2. Corrected gestational age below 32 weeks and lower birth weight 1500gr.

          3. Survivors at 7 days old.

          4. Clinically stable, in the opinion of the investigator, at the time of inclusion.

          5. That, properly informed, parents and / or legal guardians give written consent to
             allow the participation of the infant in the study and submit to the tests and
             examinations that it entails

        Exclusion Criteria:

          1. Renal malformations, cardiac or gastrointestinal prenatal or postnatal diagnosis.

          2. Chronic renal failure (serum creatinine&gt; 1.5 mg / dL or an increase of 0.3 mg / dL /
             day and / or oliguria defined as diuresis &lt;0.5 mL / kg / hour after the first day of
             life)

          3. Treatment with furosemide or dexamethasone

          4. Addison's disease.

          5. Persistent severe metabolic alkalosis.

          6. Impossibility of oral feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Botet Mussons, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judit Pich Martínez, Pharmacist</last_name>
    <phone>0034 93 227 54 00</phone>
    <phone_ext>2815</phone_ext>
    <email>jpich@clinic.ub.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francisco Botet Mussons, MD</last_name>
    <email>fbotet@clinic.ub.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Judit Pich Martínez, Pharmacist</last_name>
      <phone>0034 93 227 54 00</phone>
      <phone_ext>2815</phone_ext>
      <email>jpich@clinic.ub.es</email>
    </contact>
    <contact_backup>
      <last_name>Francisco Botet Mussons, MD</last_name>
      <email>fbotet@clinic.ub.es</email>
    </contact_backup>
    <investigator>
      <last_name>Francisco Botet Mussons, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>December 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2012</study_first_posted>
  <last_update_submitted>December 26, 2012</last_update_submitted>
  <last_update_submitted_qc>December 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Juan A. Arnaiz</investigator_full_name>
    <investigator_title>Project manager Clinical Trials Unit</investigator_title>
  </responsible_party>
  <keyword>Nephrocalcinosis</keyword>
  <keyword>Extreme premature</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Nephrocalcinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

